Advanced searches left 3/3

Erythromycin - Europe PMC

Summarized by Plex Scholar
Last Updated: 05 September 2022

* If you want to update the article please login/register

Erythromycin: an alternative for the management of oral mucositis?

BACKGROUND Theore, Oral mucositis is a common acute adverse reaction of anticancer therapy. Material and methods We searched the literature on the pathobiology of OM and the pharmacological properties of erythromycin to consider the likelihood of its use in the prevention and treatment of OM. EM has the ability to modulate oxidative stress, intervenes on the transcriptional system, and has suspended the manufacture of several cytokines that have been specifically associated with OM pathobiology. Conclusions The current report shows that EM may be safe in the treatment of OM. Experimental studies looking at the use of EM in OM should be encouraged.

Source link: https://europepmc.org/article/MED/35717620


Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms.

Significant intersubject variability was found in the latest standard-dose caffeine therapy findings, which indicates significant intersubject variability. This research sought to identify and analyze population pharmacokinetic models of caffeine in premature infants by extensive testing of covariates and then to recommend model-informed precision dosing of caffeine for this population. In this research, 129 caffeine levels from 96 premature neonates were included in this study. A nonlinear mixed effects modeling scheme conducted PPK simulations. Concomitant ERY therapy and rs2158041 under different dosage regimens, according to Monte Carlo simulations, trough concentrations of caffeine in preterm infants would be affected by concomitant ERY therapy and rs2158041. For the first time, ERY and rs2158041 were found to be associated with caffeine clearance in premature infants. These results reveal new insights into caffeine precision therapy for premature infants.

Source link: https://europepmc.org/article/MED/36029933


Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance.

However, the causes of resistance to macrolides in Bordetella paratussis and Bordetella holmesii are also unknown. Methods A series of ten clinical and reference strains of B. pertussis, B. paratussis, and B. holmesii were exposed to erythromycin for 15 weeks or 30 subculture passages. B. tussis and B. holmesii isolates demonstrated significant in vitro resistance to erythromycin within 2 to 7 weeks and 5 to 12 weeks, respectively. B. holmesii showed resistance as a result of mutations in the 23S rRNA gene, according to a Genomic analysis. The resistance mechanism in B. paratussis was hypothesized as a result of the upregulation of an efflux pump mechanism. B. holmesii and B. paratussis may be more prone to resistance after exposure to erythromycin therapy than B. pertussis, according to these results. The study of macrolide resistance in Bordetella isolates recovered from patients with pertussis, particularly persistent disease, is warranted.

Source link: https://europepmc.org/article/MED/35971665


Emergence of Erythromycin Resistant Invasive Group A Streptococcus in West Virginia, United States

ABSTRACT Combination therapy for A Streptococcus infections and clindamycin has been a mainstay in the treatment of A Streptococcus infections, but increasing macrolide resistance has restricted this therapy to strains that exhibit MLS B phenotypes. The CDC recently reported erythromycin and clindamycin resistance rates for iGAS in 2017 as over 20% in 2017. We looked at 76 iGAS isolates from 66 patients identified at J. W. emm typing was performed at Ruby Memorial Hospital in West Virginia from 2020 to 2021 using the CDC protocol and database. Both emm92 and emm11 isolates were erythromycin resistant, while the remaining 11% of resistant isolates were composed of 5 emm species. Compared to historical and national surveys, there was a change in emm-type distribution and the occurrence of macrolide-resistant isolates, which caused concern about the outbreak of emerging resistance to commonly used antibiotics used in treating iGAS infections.

Source link: https://europepmc.org/article/PPR/PPR530120


Eudragit ® L100/Polyvinyl Alcohol Nanoparticles Impregnated Mucoadhesive Films as Ocular Inserts for Controlled Delivery of Erythromycin: Development, Characterization and In Vivo Evaluation.

One of many issues associated with conventional dosage forms is the rapid removal of drugs from the cornea. The present paper sought to develop erythromycin-containing inserts in order to improve drug delivery and address the aforementioned limitation. The film-casting process was used to create the mucoadhesive films by sodium alginate, gelatin, cyclodextrin-u03b1, and u03b1 as polymeric film matrices. With more than 20 mm of blocked growth zones, the two products showed antibacterial activity against E. coli and S. aureus. During the first 120 hours of investigation, the inserts showed promising pharmacokinetics with AUC 0-120 of 30,000-36,000 bg/mL, a C max of more than 1800 u00b5g/mL at 4 h, and maintained drug concentration above the threshold of 5 g/mL. As ocular inserts, nanoparticle-containing, mucoadhesive films could be made as ocular inserts, extending the topical ocular delivery of ERY.

Source link: https://europepmc.org/article/MED/36009463

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions